Clinical Hematology International

Latest Articles

Review Article

Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

Uttam K. Rao, Brian G. Engelhardt
In Press, Uncorrected Proof, Available Online: 21 May 2020
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is...
Review Article

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Sarah A. Bird, Graham H. Jackson, Charlotte Pawlyn
Volume 2, Issue 2, June 2020, Pages 59-68
Multiple myeloma, the second most common hematological malignancy worldwide, has demonstrated dramatic improvements in outcome in the last decade. In newly diagnosed patients, induction chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care. After ASCT, the majority...
Research Article

Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation

Raheel Iftikhar, Qamar un Nisa Chaudhry, Tariq Mehmood Satti, Syed Kamran Mahmood, Tariq Ghafoor, Ghassan Umair Shamshad, Nighat Shahbaz, Mehreen Ali Khan, Tariq Azam Khattak, Jahanzeb Rehman, Muhammad Farhan, Saima Humayun, Humera Haq, Syeda Ammaara Anwaar Naqvi, Faiz Anwer, Humayoon Shafique Satti, Parvez Ahmed
Volume 2, Issue 2, June 2020, Pages 82-91
Allogeneic stem cell transplant for high-risk aplastic anemia (AA) yields inferior results using conventional cyclophosphamide (CY)-based conditioning. The use of fludarabine (Flu)-based regimens has resulted in improved outcomes in high-risk patients. Limited data are available comparing these two conditioning...
Research Article

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features

Bhagirathbhai Dholaria, Yenny Alejandra Moreno Vanegas, Nancy Diehl, Aaron C. Spaulding, Sue Visscher, Han W. Tun, Sikander Ailawadhi, Prakash Vishnu
In Press, Corrected Proof, Available Online: 23 April 2020
Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-risk DLBCL who received frontline rituximab, cycophosphamide,...
Review Article

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant

Samuel Cytryn, Maher Abdul-Hay
Volume 2, Issue 2, June 2020, Pages 49-58
Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. However, a suitable human leukocyte antigens (HLAs)-matched donor may not be available when the patient is in urgent need of a stem cell transplant. This challenge...
Review Article

The Evolving Landscape of Myelodysplastic Syndrome Prognostication

Jacob Shreve, Aziz Nazha
Volume 2, Issue 2, June 2020, Pages 43-48
Myelodysplastic syndromes (MDSs) are potentially devastating monoclonal deviations of hematopoiesis that lead to bone marrow dysplasia and variable cytopenias. Predicting severity of disease progression and likelihood to undergo acute myeloid leukemia transformation is the basis of treatment strategy....
Research Article

The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

M. Remberger, B. Grønvold, M. Ali, J. Mattsson, T. Egeland, K. U. Lundin, A. Myhre, I. Abrahamsen, D. Heldal, I. Dybedal, G. E. Tjønnfjord, T. Gedde-Dahl, Y. Fløisand
Volume 2, Issue 2, June 2020, Pages 74-81
The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological...
Research Article

Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft-Versus-Host Disease

Ehsan Shabbir, Umar Farooq, Burhan Yanes, Margarida Magalhaes-Silverman
Volume 2, Issue 2, June 2020, Pages 69-73
Graft versus host disease (GVHD) of the gut is associated with significant morbidity and mortality after allogeneic hematopoietic cell transplant (allo-HCT). No guidelines exist regarding repeat endoscopy after failure of first-line treatment with steroids. We aimed to study if repeat endoscopic biopsy...
Review Article

Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults

Cosmin Tegla, Jun Choi, Maher Abdul-Hay, Frank Cirrone, Kelli Cole, A Samer Al-Homsi
Volume 2, Issue 1, March 2020, Pages 5-12
Graft-versus-host disease (GvHD) in its acute and chronic forms continues to represent a significant barrier to the success and wide-applicability of blood and marrow transplantation as a potentially curative treatment modality for a number of benign and malignant blood conditions. Presently, calcineurin...

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Kristian T. Andersen, Maja Hinge, Agoston Gyula Szabo, Erik Segel, Tina Ormstrup, Paw C. Holdgaard, Niels Pallisgaard, Gitte Kerndrup, Torben Plesner
Volume 2, Issue 1, March 2020, Pages 35-39

Looking Ahead: Clinical Hematology International Turns One

Mohamad Mohty, Arnon Nagler, Bipin Savani
Volume 2, Issue 1, March 2020, Pages 1-1

Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation

Abraham S. Kanate, Arnon Nagler, Bipin Savani
Volume 2, Issue 1, March 2020, Pages 2-4
Due to the increasingly strict word/character restrictions enforced by most scientific publications, we identified a need for a master document illustrating the “Scientific Methods” that may be applicable to the majority of observational and registry-based studies in hematopoietic cell transplantation...
Research Article

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B. DeStefano, Christopher S. Hourigan, Catherine Lai
Volume 2, Issue 1, March 2020, Pages 27-31
Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may be particularly useful for that indication. We report here a series of ten such adult patients treated sequentially at a single...
Review Article

Emerging Therapies for the Myelodysplastic Syndromes

Jonathan Canaani
Volume 2, Issue 1, March 2020, Pages 13-17
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge. Considerable barriers to timely development of effective therapy include the diverse...
Review Article

Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells

Oluwadunni E. Emiloju, Rashmika Potdar, Vinicius Jorge, Sorab Gupta, Gabor Varadi
Volume 2, Issue 1, March 2020, Pages 18-26
Apart from peripheral blood stem cell (PBSC), umbilical cord blood (UCB) is now a recognized source of stem cells for transplantation. UCB is an especially important source of stem cells for minority populations, which would otherwise be unable to find appropriately matched adult donors. UCB has fewer...
Case Report

Human Herpes Virus-6 Encephalitis Following Autologous Blood and Marrow Transplant

Jacques Mario Azzi, Doyun Park, Maher Abdul-Hay, Kelli Cole, Frank Cirrone, Maxim Kreditor, A. Samer Al-Homsi
Volume 2, Issue 1, March 2020, Pages 32-34
Human herpesvirus-6 (HHV-6) is a highly prevalent virus that establishes lifelong latency in human hosts. Symptomatic HHV-6 reactivation rarely occurs in immunocompetent individuals and is best described in immunosuppressed patients such as recipients of bone marrow transplants (BMT). In that setting,...
Review Article

Moving Toward Continuous Therapy in Multiple Myeloma

Francesca Bonello, Giusy Cetani, Luca Bertamini, Francesca Gay, Alessandra Larocca
Volume 1, Issue 4, December 2019, Pages 189-200
The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy currently represents the standard approach for myeloma...
Research Article

Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation

Dwight D. Eplin, Anna D. Jackson, Austin M. Smith, Brent Salvig, Wichai Chinratanalab, Bipin N. Savani
Volume 1, Issue 4, December 2019, Pages 229-233
The biologic medication filgrastim is approved by the Food and Drug Administration (FDA) to mobilize hematopoietic progenitor cells (HPCs) for collection by leukapheresis for autologous hematopoietic stem cell transplant (HSCT). The FDA-approved biologic tbo-filgrastim is currently used off-label for...
Review Article

Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation

Juliana Matthews, Dwight Eplin, Bipin Savani, Barbara Gisella Carranza Leon, Leslee Matheny
Volume 1, Issue 4, December 2019, Pages 180-188
Hematopoietic stem cell transplantation (HSCT) has become a potentially curative therapy for an increasing number of malignant and non-malignant conditions. As survival rates continue to improve, the focus of patient care has shifted from managing not only immediate but also long-term complications....
Research Article

The Impact of First Complete Remission by PET-CT and Time to Next Treatment on Survival of Follicular Lymphoma Patients

Tran-Der Tan, Lun-Wei Chiou, Mau-Ching Wu, Jia-Shing Wu, Ming-Yuan Lee, Yu-Yi Huang, Shing-Su Chen
Volume 1, Issue 3, September 2019, Pages 168-172
We retrospectively analyzed the impact of initial positron emission tomography and computed tomography (PET-CT) complete remission (CR) and time to next treatment (TTNT) on patient outcome in follicular lymphoma. Between 2002 and 2014, 150 patients could be evaluated for treatment response and long-term...
Review Article

Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives

Mohammad Shahrukh Tanweer, Mahmoud Aljurf, Bipin N. Savani, Perviz K. Iqbal, Shahrukh Hashmi
Volume 1, Issue 3, September 2019, Pages 142-153
Female recipients of hematopoietic cell transplant (HCT) may develop lower genital tract (LGT) dysplasia or new malignancies. A comprehensive systematic review to delineate the occurrence and risk factors for post-HCT LGT precancer and cancer in women was conducted via electronic search of the Cochrane...
Research Article

Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument

Sandhya R. Panch, Opal L. Reddy, Katherine Li, Thejaswi Bikkani, Anusha Rao, Swathi Yarlagadda, Steven Highfill, Daniel Fowler, Richard W. Childs, Minocher Battiwalla, John Barrett, Andre Larochelle, Crystal Mackall, Nirali Shah, David F. Stroncek
Volume 1, Issue 3, September 2019, Pages 161-167
Cell separation technologies play a vital role in the graft engineering of hematopoietic cellular fractions, particularly with the rapid expansion of the field of cellular therapeutics. The CliniMACS Plus Instrument (Miltenyi Biotec) utilizes immunomagnetic techniques to isolate hematopoietic progenitor...
Review Article

Allogeneic Stem Cell Transplantation with CD34+ Cell Selection

Elisa Roldan, Miguel Angel Perales, Pere Barba
Volume 1, Issue 3, September 2019, Pages 154-160
The success of allogeneic stem cell transplant is hampered by the development of acute and chronic graft-versus-host disease (GvHD) which has direct impact on treatment-related mortality and morbidity. As a result, T cell depletion through positive selection of CD34+ cells has emerged as a promising...